

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

FOREST LABORATORIES, LLC and	)	
FOREST LABORATORIES HOLDINGS,	)	
LTD.,	)	
	)	
Plaintiffs,	)	C.A. No. 14-1119 (SLR)(SRF)
	)	CONSOLIDATED
v.	)	
	)	C.A. No. 15-0158 (SLR)(SRF)
SIGMAPHARM LABORATORIES, LLC, et	)	C.A. No. 15-0430 (SLR)(SRF)
al.,	)	C.A. No. 14-1504 (SLR)(SRF)
	)	C.A. No. 14-1266 (SLR)(SRF)
Defendants.	)	

**NOTICE OF CROSS-APPEAL TO THE UNITED  
STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT**

Notice pursuant to 28 U.S.C. § 1295(a)(1) and Federal Rules of Appellate Procedure 3 and 4(a)(3) is given that Plaintiffs Forest Laboratories, LLC (f/k/a Forest Laboratories, Inc.) and Forest Laboratories Holdings, Ltd. (collectively, “Plaintiffs”) hereby cross-appeal to the United States Court of Appeals for the Federal Circuit from the following:

1) the district court’s final judgment of non-infringement of claims 4, 9, and 10 of U.S. Patent No 5,763,476 (the “’476 patent”) as to Defendants Alembic Pharmaceuticals Ltd., Alembic Global Holding SA, Alembic Pharmaceuticals, Inc. (collectively, “Alembic”), and Breckenridge Pharmaceutical, Inc. (“Breckenridge”), entered on July 11, 2017 pursuant to Federal Rule of Civil Procedure 54(b) (D.I. 325 in C.A. No. 14-1119 (SLR)(SRF) LEAD CASE; D.I. 14 in C.A. No. 15-158 (SLR)(SRF); and D.I. 23 in C.A. 14-1504 (SLR)(SRF));

2) those issues decided adversely to Plaintiffs with respect to the district court’s construction of claim 4 the ’476 patent, and the claims depending therefrom, as set forth in the district court’s Memorandum Order Re: Claim Construction, dated January 29, 2016 (D.I. 133 in C.A. 14-1119 (SLR)(SRF) LEAD CASE).

3) any and all other adverse findings, holdings, rulings, determinations, conclusions, orders, claim constructions, opinions, and decisions, whether oral or written, decided adversely to Plaintiffs, including those relating to, incorporated in, antecedent to, pertinent to, or ancillary to the district court's opinion and order entered on June 30, 2017 (D.I. 322 and 323 in C.A. 14-1119 (SLR)(SRF) LEAD CASE) and the district court's final judgment entered on July 11, 2017 (D.I. 325 in C.A. No. 14-1119 (SLR)(SRF) LEAD CASE; D.I. 14 in C.A. No. 15-158 (SLR)(SRF); D.I. 24 in C.A. No. 15-430 (SLR)(SRF); D.I. 23 in C.A. 14-1504 (SLR)(SRF); and D.I. 26 in 14-1266 (SLR)(SRF), and including, but not limited to the district court's Memorandum Order Re: Claim Construction entered on January 29, 2016 (D.I. 133 in C.A. No. 14-1119 (SLR)(SRF) LEAD CASE); the Joint Stipulation of Entry and Order of Adverse Judgment and Dismissal of Counterclaims of U.S. Patent Nos. 7,741,358 and 8,022,228 as to Defendants Hikma Pharmaceuticals, LLC, Hikma Pharmaceuticals, PLC, and West-Ward Pharmaceutical Corp. (collectively, "Hikma") ordered by the district court on March 28, 2016 (D.I. 174 in C.A. 14-1119 (SLR)(SRF) LEAD CASE); the Judgment of Non-Infringement and Order of Dismissal of Counterclaims as to Breckenridge ordered by the district court on April 5, 2016 (D.I. 178 in C.A. 14-1119 (SLR)(SRF) LEAD CASE); and the Joint Stipulation of Entry and Order of Adverse Judgment and Dismissal of Counterclaims of U.S. Patent Nos. 7,741,358 and 8,022,228 as to Sigmapharm Laboratories, LLC ("Sigmapharm") ordered by the district court on April 18, 2016 (D.I. 181 in C.A. 14-1119 (SLR)(SRF) LEAD CASE).

Included herewith is payment of the filing fee (\$5.00) and the docketing fee (\$500.00) as required by 28 U.S.C. §§ 1913, 1917, Federal Circuit Rule 52(a)(3)(A), and Federal Rule of Appellate Procedure 3(e).

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Maryellen Noreika

Jack B. Blumenfeld (#1014)

Maryellen Noreika (#3208)

1201 North Market Street

P.O. Box 1347

Wilmington, DE 19899

(302) 658-9200

jblumenfeld@mnat.com

mnoreika@mnat.com

*Attorneys for Plaintiffs*

OF COUNSEL:

Charles E. Lipsey

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, LLP

Two Freedom Square

11955 Freedom Drive.

Reston, VA 20190-5675

(571) 203-2700

Howard W. Levine

Sanya Sukduang

Jonathan R. Davies

Courtney B. Casp

Jorge F. Gonzalez

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, LLP

901 New York Avenue, NW

Washington, DC 20001-4413

(202) 408-4000

August 9, 2017

**CERTIFICATE OF SERVICE**

I hereby certify that on August 9, 2017, I caused the foregoing to be electronically filed with the Clerk of the Court using CM/ECF, which will send notification of such filing to all registered participants.

I further certify that I caused copies of the foregoing document to be served on August 9, 2017, upon the following in the manner indicated:

John C. Phillips, Jr., Esquire  
David A. Bilson, Esquire  
Megan C. Haney, Esquire  
PHILLIPS, GOLDMAN, McLAUGHLIN & HALL, P.A.  
1200 North Broom Street  
Wilmington, DE 19806-4204  
*Attorneys for Sigmapharm Laboratories, LLC*

*VIA ELECTRONIC MAIL*

John G. Simon, Esquire  
Anthony G. Simon, Esquire  
Anthony R. Friedman, Esquire  
Benjamin R. Askew, Esquire  
Timothy D. Krieger, Esquire  
Michael P. Kella, Esquire  
THE SIMON LAW FIRM, P.C.  
800 Market Street, Suite 1700  
St. Louis, MO 63101  
*Attorneys for Sigmapharm Laboratories, LLC*

*VIA ELECTRONIC MAIL*

Karen E. Keller, Esquire  
Jeffrey T. Castellano, Esquire  
SHAW KELLER LLP  
1105 North Market Street, 12th Floor  
Wilmington, DE 19801  
*Attorneys for Hikma Pharmaceuticals, LLC,  
Hikma Pharmaceuticals, PLC, and West-Ward  
Pharmaceutical Corp.*

*VIA ELECTRONIC MAIL*

Imron T. Aly, Esquire  
Joel M. Wallace, Esquire  
Helen H. Ji, Esquire  
SCHIFF HARDIN LLP  
233 South Wacker Drive, Suite 6600  
Chicago, IL 60606  
*Attorneys for Hikma Pharmaceuticals, LLC,  
Hikma Pharmaceuticals, PLC, and West-Ward  
Pharmaceutical Corp.*

*VIA ELECTRONIC MAIL*

John K. Hsu, Esquire  
SCHIFF HARDIN LLP  
901 K. Street NW, Suite 700  
Washington, DC, 20001  
*Attorneys for Hikma Pharmaceuticals, LLC,  
Hikma Pharmaceuticals, PLC, and West-Ward  
Pharmaceutical Corp.*

*VIA ELECTRONIC MAIL*

Richard D. Kirk, Esquire  
Stephen B. Brauerman, Esquire  
Sara E. Bussiere, Esquire  
BAYARD P.A.  
222 Delaware Avenue, Suite 900  
Wilmington, DE 19801  
*Attorneys for Breckenridge Pharmaceutical, Inc.*

*VIA ELECTRONIC MAIL*

Beth D. Jacob, Esquire  
Clifford Katz, Esquire  
Malavika A. Rao, Esquire  
KELLEY DRYE & WARREN LLP  
101 Park Avenue  
New York, NY 10178  
*Attorneys for Breckenridge Pharmaceutical, Inc.*

*VIA ELECTRONIC MAIL*

Douglass C. Hochstetler, Esquire  
KELLEY DRYE & WARREN LLP  
333 West Wacker Drive, 26<sup>th</sup> Floor  
Chicago, IL 60606  
*Attorneys for Breckenridge Pharmaceutical, Inc.*

*VIA ELECTRONIC MAIL*

Robert F. Vroom, Esquire  
BRECKENRIDGE PHARMACEUTICAL, INC.  
60 East 42<sup>nd</sup> Street, Suite 5210  
New York, NY 10165  
*Attorneys for Breckenridge Pharmaceutical, Inc.*

*VIA ELECTRONIC MAIL*

Karen L. Pascale, Esquire  
Pilar G. Kraman, Esquire  
YOUNG CONAWAY STARGATT & TAYLOR LLP  
Rodney Square  
1000 North King Street  
Wilmington, DE 19801  
*Attorneys for Defendants Alembic  
Pharmaceuticals Ltd., Alembic Global Holding SA  
and Alembic Pharmaceuticals, Inc.*

VIA ELECTRONIC MAIL

Steven J. Lee, Esquire  
Michael K. Levy, Esquire  
Paul M. Richter, Esquire  
Ksenia Takhistova, Esquire  
ANDREWS KURTH KENYON LLP  
One Broadway  
New York, NY 10004-1007  
*Attorneys for Defendants Alembic  
Pharmaceuticals Ltd., Alembic Global Holding SA  
and Alembic Pharmaceuticals, Inc.*

VIA ELECTRONIC MAIL

Neal C. Belgam, Esquire  
Eve H. Ormerod, Esquire  
SMITH KATZENSTEIN & JENKINS LLP  
1000 West Street, Suite 1501  
Wilmington, DE 19801  
*Attorneys for Defendants Amneal  
Pharmaceuticals, LLC, Amneal Pharmaceuticals  
of New York, LLC and Amneal Pharmaceuticals  
Co. India PVT. LTD.*

VIA ELECTRONIC MAIL

Michael R. Dzwonczyk, Esquire  
Azy S. Kokabi, Esquire  
Aiyda Ghahramani, Esquire  
SUGHRUE MION, PLLC  
2100 Pennsylvania Avenue, NW  
Washington, DC 20037  
*Attorneys for Defendants Amneal  
Pharmaceuticals, LLC, Amneal Pharmaceuticals  
of New York, LLC and Amneal Pharmaceuticals  
Co. India PVT. LTD.*

VIA ELECTRONIC MAIL

/s/ Maryellen Noreika  
Maryellen Noreika (#3208)